Derma Medical LLP

Noveltreat 2.4 mg Injection (Semaglutide) is a prescription medication indicated for chronic weight management and improvement of glycemic control in adults with obesity, overweight conditions, or type 2 diabetes mellitus. It contains Semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate appetite, food intake, and blood glucose levels. The injection is formulated for subcutaneous administration and is typically used as part of a comprehensive treatment program that includes a reduced-calorie diet and increased physical activity.

Noveltreat 1.7 mg Injection (Semaglutide) is a prescription medication used for chronic weight management and improvement of glycemic control in adults with obesity, overweight conditions, or type 2 diabetes mellitus. It contains Semaglutide 1.7 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate appetite, calorie intake, and blood glucose levels. The medication is intended for subcutaneous administration and is generally used as part of a comprehensive treatment plan including a balanced diet and regular physical activity.

Noveltreat 1 mg Injection (Semaglutide) is a prescription medication used for the management of type 2 diabetes mellitus and chronic weight management in adults. It contains Semaglutide 1 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose levels and control appetite. The injection is formulated for subcutaneous administration and is typically used as part of a comprehensive treatment plan that includes a balanced diet and regular physical activity.

Noveltreat 0.5 mg Injection (Semaglutide) is a prescription medication used for the management of type 2 diabetes mellitus and chronic weight management in adults. It contains Semaglutide 0.5 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and appetite. The injection is designed for subcutaneous administration and is typically used as part of a comprehensive treatment program that includes diet control and regular physical activity.

Noveltreat 0.25 mg Injection (Semaglutide) is a GLP-1 receptor agonist medication used for the management of obesity and improvement of glycemic control in adults with type-2 diabetes mellitus. It contains Semaglutide 0.25 mg in a sterile solution for subcutaneous administration and is typically used as the initial starting dose in semaglutide therapy to help the body gradually adjust to treatment before dose escalation.

Semasize 1.7 mg Injection (Semaglutide) is a prescription medication used for chronic weight management and improvement of glycemic control in adults with obesity, overweight conditions, or type 2 diabetes mellitus. It contains Semaglutide 1.7 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose levels, reduce appetite, and support effective weight management. The medication is formulated for subcutaneous administration and is typically prescribed as part of a comprehensive treatment plan including diet control and regular physical activity.

Semasize 1 mg Injection (Semaglutide) is a prescription medication used for the management of type 2 diabetes mellitus and chronic weight management in adults. It contains Semaglutide 1 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose levels and control appetite. The injection is formulated for subcutaneous administration and is typically prescribed as part of a comprehensive treatment program that includes a balanced diet and regular physical activity.

Semasize 1 mg Injection is usually administered once weekly on the same day each week using a prefilled injection pen designed for convenient and accurate dosing. The injection is given subcutaneously in the abdomen, thigh, or upper arm, allowing patients to self-administer the medication easily under medical guidance.

Semasize 2 mg Injection (Semaglutide) is a prescription medication used for chronic weight management and improvement of glycemic control in adults with obesity, overweight conditions, or type 2 diabetes mellitus. It contains Semaglutide 2 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose levels, suppress appetite, and support sustained weight reduction. The medication is intended for subcutaneous administration and is usually prescribed as part of a comprehensive treatment plan that includes diet control and regular physical activity.

Semasize 2 mg Injection is typically prescribed as a higher maintenance dose following gradual escalation from lower strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg). The injection is administered once weekly on the same day each week and can be given subcutaneously in the abdomen, thigh, or upper arm using a prefilled injection pen designed for convenient and accurate dosing.

Ozempic 0.25 mg Injection is a subcutaneous injectable medication containing Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist developed for the management of Type 2 Diabetes Mellitus and weight management in adults. It is designed for once-weekly administration, providing effective glycemic control while helping to regulate appetite and promote gradual, sustainable weight loss.

The 0.25 mg dose is primarily used as a starting dose for patients initiating GLP-1 therapy. This low initial dose helps improve tolerability and minimizes gastrointestinal side effects, such as nausea, vomiting, or diarrhea, which are commonly observed when starting GLP-1 receptor agonists.

Sundae Vial 4 mg / 3 mL Injection is a premium injectable formulation containing Semaglutide, designed for the management of type 2 diabetes and weight management in adults. It belongs to the class of GLP-1 receptor agonists, which act by mimicking the natural hormone glucagon-like peptide-1 (GLP-1) to regulate key metabolic functions in the body.

Sundae Vial 4 mg / 3 mL Injection is supplied in a 3 mL sterile vial, which provides a convenient multi-dose format for clinical or home-care use under the guidance of a healthcare professional. Each vial contains a total of 4 mg of semaglutide, allowing for precise dosing according to the patient’s prescribed regimen. The neck-type vial ensures compatibility with standard syringes, and the formulation is carefully manufactured to ensure purity, potency, and stability throughout its shelf life.

Ozempic 0.5 mg Injection contains Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of Type 2 Diabetes in adults. It helps control blood glucose levels by stimulating insulin secretion, reducing glucagon release, and slowing gastric emptying, which collectively improves glycemic control and supports weight reduction in many patients.

This medication is supplied as a pre-filled, multi-dose injection pen designed for once-weekly subcutaneous administration. The injection is typically administered under the skin of the abdomen, thigh, or upper arm. The 0.5 mg strength is commonly prescribed after the initial titration dose to provide effective and sustained blood glucose control while minimizing gastrointestinal side effects.

Semanext 15 mg Injection is a high-strength, long-acting GLP-1 receptor agonist formulation containing Semaglutide, designed for the management of Type 2 Diabetes Mellitus and weight management in adults. This medication is provided as a subcutaneous injection and is formulated to support once-weekly dosing, ensuring consistent blood glucose control and promoting gradual weight loss.
Semanext 15 mg Injection is suitable for adults with type 2 diabetes who require advanced glycemic control and have already tolerated lower doses of semaglutide therapy. It is also utilized in medical weight-management programs under the supervision of a healthcare professional.

Semanat 2 mg Vial Injection is a high-strength injectable formulation containing Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist, indicated for the management of Type 2 Diabetes Mellitus and weight management in adults. Supplied as a vial for subcutaneous injection, it provides precise dosing for patients who require advanced glycemic control or for use in clinical and hospital settings.
Semanat 2 mg Vial Injection is particularly prescribed for adults with type 2 diabetes who need maximum therapeutic dosing after titration from lower strengths. It can also be used in weight-management programs under the supervision of a healthcare professional.

Semanat 4 mg Vial Injection is a high-strength injectable formulation containing Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist, specifically designed for the management of Type 2 Diabetes Mellitus and weight management in adults. Supplied as a sterile vial for subcutaneous injection, it provides precise dosing for patients who require maximum glycemic control or for use in clinical and hospital settings.

Semanat 4 mg Vial Injection is generally prescribed for adults with type 2 diabetes who require advanced glycemic management after lower-dose semaglutide therapy or for patients enrolled in supervised weight-management programs requiring high-dose therapy under medical supervision.

Extensior 0.5 mg Injection is a subcutaneous injectable medication containing Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist, indicated for the management of Type 2 Diabetes Mellitus and weight management in adults. This formulation is designed for once-weekly administration, providing effective and sustained glycemic control while promoting appetite regulation and gradual weight reduction.

The 0.5 mg dose is typically used as the intermediate dose after initial therapy with 0.25 mg, allowing patients to achieve improved glycemic control while maintaining tolerability. It serves as a key step in dose escalation toward higher therapeutic doses such as 1 mg, 1.7 mg, or 2 mg, depending on individual patient requirements.

Bluvial 2 mg/1.5 mg Injection is a high-quality injectable medication designed to support effective management of metabolic health conditions, particularly those related to blood sugar control and weight management. It is formulated with advanced pharmaceutical standards to ensure optimal efficacy, safety, and patient compliance. The injection is commonly used as part of a comprehensive treatment plan that includes proper diet, physical activity, and medical supervision.

Bluvial 2 mg/1.5 mg Injection is manufactured under strict quality control and pharmaceutical manufacturing standards to ensure purity, stability, and reliability. Each dose is carefully formulated to deliver accurate strength and effective performance. The injection is typically administered subcutaneously and is designed for convenient dosing, making it suitable for patients who require regular injectable therapy.

Sundae Vial 2 mg Injection contains Semaglutide, a modern and effective medication widely used for the management of metabolic conditions such as type 2 diabetes and weight management. It belongs to the class of GLP-1 receptor agonists, which mimic the action of the natural hormone glucagon-like in the body. This mechanism helps regulate blood sugar levels, improve insulin secretion, and reduce excessive appetite.
The medication is supplied in a sterile injectable vial containing 2 mg of semaglutide, intended for subcutaneous administration. It is typically injected into areas such as the abdomen, thigh, or upper arm, as directed by a healthcare professional. Because of its long-acting properties, semaglutide provides sustained therapeutic effects that help maintain better metabolic control over time.

Semasize Cartridge Plus 1.7 mg Injection is a pre-filled cartridge injection containing Semaglutide, a long-acting GLP-1 (Glucagon-Like Peptide-1) receptor agonist indicated for the management of Type 2 Diabetes Mellitus and weight management in adults. The cartridge is designed for use with compatible pen devices, ensuring precise dosing, convenience, and ease of administration, making it suitable for once-weekly injections.
Semasize Cartridge Plus 1.7 mg is commonly prescribed for adults with type 2 diabetes who require advanced glycemic control and have already tolerated lower doses of semaglutide therapy. It can also be incorporated into physician-supervised weight management programs for patients who require additional metabolic support.

Semasize Cartridge 1 mg Injection is a pre-filled cartridge injection containing Semaglutide, a potent GLP-1 receptor agonist used in the management of Type 2 Diabetes Mellitus and medical weight management in adults. Designed for use with compatible pen devices, this cartridge offers precise dosing and easy administration, making it convenient for patients who require once-weekly injections for effective glycemic control.

Semaglutide, the active ingredient in Semasize 1 mg, works by mimicking the body’s natural GLP-1 hormone. It stimulates insulin secretion in response to elevated blood glucose, suppresses glucagon secretion to reduce excess hepatic glucose production, slows gastric emptying, and reduces appetite. These combined effects help maintain stable blood glucose levels, reduce post-meal glucose spikes, and support gradual, sustainable weight loss.

Semasize Cartridge Plus 2.4 mg Injection is a high-strength, pre-filled cartridge injection containing Semaglutide, a long-acting GLP-1 receptor agonist designed for the management of Type 2 Diabetes Mellitus and weight management in adults. The cartridge is intended for use with compatible pen devices, offering accurate dosing, ease of administration, and convenience, making it suitable for once-weekly injections.
Semasize Cartridge Plus 2.4 mg is particularly prescribed for adults with type 2 diabetes who require maximum glycemic control after titration from lower doses of semaglutide. It is also suitable for patients enrolled in supervised weight-management programs seeking significant metabolic and appetite control benefits.